| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 03/11/2010 | US20100062024 Biologically Active Hemagglutinin From Type A Clostridium Botulinum and Methods of Use |
| 03/11/2010 | US20100061997 Transgenic Non-Human Animals Expressing A Truncated Activin Type II Receptor |
| 03/11/2010 | US20100061985 Antagonists of tweak and of tweak receptor and their use to treat immunological disorders |
| 03/11/2010 | US20100061942 Compositions and Methods for Modulating Store-Operated Calcium Entry |
| 03/10/2010 | EP2161282A1 Peptide analogues of PACAP |
| 03/10/2010 | EP2161280A2 Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications |
| 03/10/2010 | EP2013166B1 N-carbamoylmethyl-4(r)-phenyl-2-pyrrolidinone, method of its preparation and pharmaceutical use |
| 03/10/2010 | CN101664388A transnasal transport/immunisation with highly adaptable carriers |
| 03/09/2010 | US7674775 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants |
| 03/09/2010 | CA2407972C Azabicyclic carbamates and their use as alpha-7 nicotinic acetylcholine receptor agonists |
| 03/04/2010 | WO2010024258A1 Ring-fused azole derivative having pi3k-inhibiting activity |
| 03/04/2010 | WO2009145590A3 Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof |
| 03/04/2010 | US20100056604 Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv |
| 03/04/2010 | US20100056459 Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway |
| 03/04/2010 | US20100055214 Method for increasing blood flow to mammalian skeletal muscle by administering l-argnine, crataegus extract, artichoke flavonoids and gymnostemma pentaphyllum extract |
| 03/04/2010 | US20100055176 Method of Treating Fibromyalgia or Associated Functional Symptoms of Fibromyalgia |
| 03/02/2010 | US7671180 Heparin binding protein for use in diagnosis, prvention and treatment of cell proliferative, liver, neurodegeneartive, inflammatory and pancreatic disorders; wound healing agents |
| 03/02/2010 | US7671177 Botulinum neurotoxin type E having increased biological half-life for use treatment and prevention of autonomic, neuromuscular and pain disorders |
| 03/02/2010 | US7671087 Amines that inhibit a mammalian anandamide transporter, and methods of use thereof |
| 03/02/2010 | US7671074 Have an affinity for the gabapentin binding site and can be used to treat conditions such as pain, epilepsy, migraine and others; N-{amino-[pyridin-2-yl-methyl)-amino]-methylene}-4-methylbenzenesulfonamide |
| 02/25/2010 | WO2010021064A1 Therapeutic agent for fibromyalgia syndrome and therapeutic agent for pain due to vascular smooth muscle spasm |
| 02/25/2010 | US20100048660 Treatment of duchenne muscular dystrophy |
| 02/25/2010 | US20100048588 Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
| 02/25/2010 | US20100047259 Follistatin domain containing proteins |
| 02/25/2010 | US20100047211 Method of growth of mesenchymal cells under non-adherent conditions for clinical applications |
| 02/24/2010 | EP2155207A2 N-acetyl mannosamine as a therapeutic agent |
| 02/24/2010 | EP2155184A2 Prophylactic and therapeutic use of sirtuin inhibitors in tnf-alpha mediated pathologies |
| 02/23/2010 | USRE41150 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors; compounds based on thieno(4,3,2-ef)(2)benzazepin-6-one |
| 02/23/2010 | US7667021 Neutralizing human anti-IGFR antibody |
| 02/23/2010 | US7667008 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 02/23/2010 | US7667007 αvβ3-specific antibodies |
| 02/23/2010 | US7666647 Unphosphorylated glycogen synthase kinase-3-g-beta (GSK) from baculovirus overexpression system; competitive binding; diabetes, Alzheimer's disease |
| 02/23/2010 | US7666422 Methods for the treatment of cancer using anti-CD40 antibodies |
| 02/23/2010 | CA2446890C Deuterated 3-piperidinopropiophenones and pharmaceutical drugs containing these compounds |
| 02/18/2010 | WO2010019911A2 1,4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions |
| 02/18/2010 | WO2010018856A1 Prophylactic/ameliorating or therapeutic agent for cannabinoid receptor-related disease |
| 02/18/2010 | WO2010018614A1 Hydrophilic amino acid-containing preparation having improved taste |
| 02/18/2010 | WO2010018280A1 Use of p2x7 receptor antagonists to promote axonal growth and ramification |
| 02/18/2010 | US20100041746 Novel use of organic compounds |
| 02/18/2010 | US20100041721 Selective androgen receptor modulators |
| 02/18/2010 | US20100041665 N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |
| 02/18/2010 | CA2734305A1 1,4-benzoxazine compounds and derivatives thereof as therapeutic drugs for the treatment of neurodegenerative conditions |
| 02/17/2010 | EP2152748A1 Anti-notch1 nrr antibodies and methods using same |
| 02/17/2010 | EP1511737B1 Aryloximes |
| 02/16/2010 | US7662825 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma |
| 02/16/2010 | US7662817 Psychological disorders; central nervous system disorders; antidepressants; anxiolytic agents; stress reliever; irritable bowel syndrome |
| 02/16/2010 | CA2402436C Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 02/11/2010 | WO2010017135A2 Novel forms of eperisone |
| 02/11/2010 | WO2010016590A1 Therapeutic or prophylactic agent for generalized pain syndrome |
| 02/11/2010 | US20100035865 Sulfonamides and Pharmaceutical Compositions Thereof |
| 02/11/2010 | US20100035842 Amino alcohol compounds or phosphonic acid derivatives thereof |
| 02/10/2010 | EP2150117A1 Methods and compositions for mitochondrial replacement therapy |
| 02/10/2010 | EP1490365B1 Azaindoles as inhibitors of c-jun n-terminal kinases |
| 02/10/2010 | CN100588647C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 02/09/2010 | US7659407 Pharmaceutical compounds |
| 02/09/2010 | US7659282 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 02/09/2010 | US7659272 N-[phenyl or heteroaryl carbonoyl pyridyl] arylsulfonamides; antiinflammatory, antianaphylactic agents; transplant rejection, gastointestinal, respriatory system and skin disorders |
| 02/09/2010 | CA2663141C Creatine pyroglutamic acid salts and methods for their production and use in individuals |
| 02/09/2010 | CA2386297C Bicyclic amino acids as pharmaceutical agents |
| 02/04/2010 | WO2010014798A2 Pyrimidotriazinediones and pyrimidopyrimidinediones and methods of using the same |
| 02/04/2010 | WO2010013494A1 Pharmaceutical composition comprising botulinum neurotoxin preparation incapable of being synaptically transported, and use thereof |
| 02/04/2010 | US20100029639 Ion channel modulating compounds and uses thereof |
| 02/04/2010 | US20100029631 Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient |
| 02/04/2010 | US20100028349 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity |
| 02/03/2010 | EP2148641A1 Treatment of movement disorders by a combined use of botulinum toxin and muscle stimulation |
| 02/03/2010 | EP1511742B1 Kinase inhibitors |
| 02/02/2010 | US7655763 Neutralizing antibodies against GDF-8 and uses therefor |
| 02/02/2010 | US7655674 Hedgehog antagonists that inhibit the hedgehog pathway in a smoothened gain-of-function cell with an IC50 within a factor of 20, 10, or even a factor of 5, of the IC50 with which they inhibit the hedgehog pathway in a patched-null cell |
| 02/02/2010 | US7655628 Method for treating liver cirrhosis or interstitial pulmonary fibrosis |
| 02/02/2010 | US7655463 Treating neuropathic pain, particularly diabetic peripheral neuropathy, by administering a truncated neublastin polypeptide; activating a RET receptor tyrosine kinase |
| 02/02/2010 | CA2494583C Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid |
| 02/02/2010 | CA2396158C Dipeptide nitrile cathepsin k inhibitors |
| 01/28/2010 | WO2010010934A1 Heterocyclidene derivative having p-substituted arylacetamide |
| 01/28/2010 | WO2010010127A1 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
| 01/28/2010 | US20100021482 Novel death associated proteins, and thap1 and par4 pathways in apoptosis control |
| 01/28/2010 | US20100021462 Gasp1: a follistatin domain containing protein |
| 01/28/2010 | CA2730751A1 Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
| 01/27/2010 | EP1362106B1 Streptococcus pyogenes polypeptides and corresponding dna fragments |
| 01/27/2010 | CN100584819C Substituted 4-aminocyclohexanol derivatives |
| 01/26/2010 | US7652060 Small molecule rotamase enzyme inhibitors |
| 01/26/2010 | US7652045 Activator of peroxisome proliferator-activated receptor δ |
| 01/26/2010 | CA2481012C Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| 01/26/2010 | CA2447099C Delivery of compounds for the treatment of migraine through an inhalation route |
| 01/26/2010 | CA2434731C Modular infusion device and method |
| 01/26/2010 | CA2422889C Method for the treatment of neurological and neuropsychological disorders |
| 01/26/2010 | CA2350031C N-arylsulfonylamino acid omega-amides |
| 01/26/2010 | CA2201841C Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| 01/21/2010 | WO2010009312A2 Compositions comprising mg29 nucleic acids, polypeptides and associated methods of use |
| 01/21/2010 | WO2010007972A1 Novel indole derivative having carbamoyl group, ureide group and substituted oxy group |
| 01/21/2010 | WO2010007788A1 Glycyrrhetinic acid derivative and use thereof |
| 01/21/2010 | WO2010007316A2 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 01/21/2010 | WO2009146033A3 Compositions and methods for modulating smn activity |
| 01/21/2010 | WO2009144481A3 Peptide conjugates for delivery of biologically active compounds |
| 01/21/2010 | US20100016332 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
| 01/21/2010 | US20100016216 Adiponectin and uses thereof |
| 01/21/2010 | US20100016215 Compound and method for treating myotonic dystrophy |
| 01/21/2010 | US20100015254 Use of tea-derived, theaflavin enriched extract to increase exercise performance and reduce exercise recovery time |
| 01/21/2010 | US20100015118 Supplement formula to prevent and deter muscle trauma and method of using same |
| 01/21/2010 | CA2730959A1 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 01/21/2010 | CA2730923A1 Compositions comprising mg29 nucleic acids, polypeptides and associated methods of use |